tiprankstipranks
Trending News
More News >
Addex Therapeutics (ADXN)
NASDAQ:ADXN
Advertisement

Addex Therapeutics (ADXN) Price & Analysis

Compare
73 Followers

ADXN Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.07%99.93%
Insiders
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors

ADXN FAQ

What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $6.51 and its highest was $13.27 in the past 12 months.
    What is Addex Therapeutics’s market cap?
    Addex Therapeutics’s market cap is $14.23M.
      When is Addex Therapeutics’s upcoming earnings report date?
      Addex Therapeutics’s upcoming earnings report date is Sep 01, 2025 which is in 46 days.
        How were Addex Therapeutics’s earnings last quarter?
        Currently, no data Available
        Is Addex Therapeutics overvalued?
        According to Wall Street analysts Addex Therapeutics’s price is currently same. Get more investment ideas with TipRanks Premium
          Does Addex Therapeutics pay dividends?
          Addex Therapeutics does not currently pay dividends.
          What is Addex Therapeutics’s EPS estimate?
          Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Addex Therapeutics have?
          Addex Therapeutics has 1,536,287 shares outstanding.
            What happened to Addex Therapeutics’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Addex Therapeutics?
            Among the largest hedge funds holding Addex Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Addex Therapeutics’s shares valued at 0.

              Company Description

              Addex Therapeutics

              Addex Therapeutics (ADXN) is a clinical-stage pharmaceutical company focused on the development of innovative oral small molecule drugs for neurological disorders. The company operates primarily in the biotechnology and pharmaceuticals sector, with a core emphasis on allosteric modulation-based therapies. Addex Therapeutics is engaged in developing a pipeline of compounds targeting central nervous system disorders, including Parkinson's disease, epilepsy, and other neurodegenerative and psychiatric conditions.

              ADXN Earnings Call

              Q1 2025
              0:00 / 0:00
              Earnings Call Sentiment|Neutral
              The earnings call highlighted significant strategic partnerships and advancements in drug development programs, notably the successful Series A financing for Neurosterix and progress in the GABAB PAM program. However, challenges remain with decreased income and cash limitations for unpartnered programs, indicating a balanced outlook.Read More>
              Similar Stocks
              Company
              Price & Change
              Follow
              Plus Therapeutics
              Minerva Neurosciences
              GeoVax Labs
              Moleculin Biotech
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis